SCHEMBL13664393

SCHEMBL13664393

Cc1ccc(C(=O)c2nn(-c3ccc(Cl)cc3)c(NCCCNC(=O)c3nc4ncccn4n3)c2C#N)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
MAPT P10636 5/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 2/20 0.39
TP53 P04637 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 2/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
USP2 O75604 1/20 0.36
HPGD P15428 4/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664333 0.90 MAPT (0.42) LMNAMAPTNPC1TP53MEN1
SCHEMBL13664386 0.86 MEN1 (0.40) MAPTHSD17B10MEN1KMT2APOLB
SCHEMBL13664330 0.85 KMT2A (0.52) MAPTSMN1; SMN2MEN1KMT2APOLB
SCHEMBL13664143 0.85 POLB (0.46) LMNAMAPTNPC1MEN1KMT2A
SCHEMBL13664373 0.85 POLB (0.46) LMNAMAPTNPC1MEN1KMT2A
SCHEMBL13664329 0.83 CNR1 (0.46) LMNAMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL13664403 0.83 L3MBTL1 (0.46) LMNAMAPTNPC1MEN1KMT2A
SCHEMBL13664412 0.83 ADRA1A (0.41) MAPTRAB9ANPC1HSD17B10MEN1
SCHEMBL13664332 0.83 L3MBTL1 (0.43) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL13664379 0.82 TDP1 (0.42) LMNAMAPTRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R LMNA 4188/4885MAPT 4701/4885RAB9A 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.